CN103958541A - 5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐 - Google Patents
5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐 Download PDFInfo
- Publication number
- CN103958541A CN103958541A CN201280050955.7A CN201280050955A CN103958541A CN 103958541 A CN103958541 A CN 103958541A CN 201280050955 A CN201280050955 A CN 201280050955A CN 103958541 A CN103958541 A CN 103958541A
- Authority
- CN
- China
- Prior art keywords
- acid
- hydroxy
- imidazol
- ethylamino
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AVFNYTPENXWWCA-YBJNSTMZSA-N CC(C)CCCC(C)[C@@H](CC1)[C@@](C)(CC2)C1C(C[C@H]1NCCc3cnc[nH]3)C2[C@@](C)(CC[C@@H](C2)O)[C@@]12O Chemical compound CC(C)CCCC(C)[C@@H](CC1)[C@@](C)(CC2)C1C(C[C@H]1NCCc3cnc[nH]3)C2[C@@](C)(CC[C@@H](C2)O)[C@@]12O AVFNYTPENXWWCA-YBJNSTMZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐、其制备和应用。
Description
本发明涉及5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐、其制备和应用。
药物活性化合物5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇以Dendrogenin A的名字为人所知。其结构式如下:
Dendrogenin A以游离碱的形式公开于WO03/89449和Medina等人的J.Med.Chem.,2009中。游离碱在水中的溶解度为0.47毫克/毫升。
然而,Dendrogenin A的酸加成盐至今从未披露。
本发明涉及Dendrogenin A的酸加成盐,其具有在水中的显著溶解度(比游离碱的溶解度高达130倍)。
由于其显著的溶解度,当本发明的盐被注射时,预计其比游离碱更具有生物可利用性,从而允许更高的剂量给药。
本发明的盐是5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇与选自下组的酸形成的酸加成盐:
-无机酸,
-包含不多于8个碳原子的无环脂肪族羧酸或磺酸,以及
-包含不超过4个芳基基团的芳族羧酸或磺酸。
本发明的盐可以具有1至70毫克/毫升的在水中溶解度,特别是1.4至65毫克/毫升,更具体地:
-在35至65毫克/毫升之间,如与L-乳酸,丙二酸,L-苹果酸或酒石酸(D或L)形成的盐;
-在20至35毫克/毫升之间,如苯磺酸,苯甲酸,琥珀酸,4-甲基苯磺酸或盐酸;
-在10至20毫克/嘉升之间,如硫酸,富马酸,戊二酸,或甲磺酸;
-或在1.4至10毫克/毫升之间,如柠檬酸,乙酸或双羟萘酸。
本发明的盐可以通过DendrogeninA的游离碱与上面列出的酸之一的反应来制备。用于该反应的溶剂可以是例如乙醇,水或甲苯。其可在反应过程中被加热。所得的盐可按照本领域技术人员公知的方法回收。
本发明的DendrogeninA的酸加成盐可以由无机酸形成。
在一个实施方案中,所述无机酸不包括盐酸。
优选的无机酸选自盐酸和硫酸。
Dendrogenin A与无机酸形成的酸加成盐可以具有15至25毫克/毫升的在水中溶解度。
本发明的Dendrogenin A的酸加成盐也可以由包含不超过8个碳原子的无环脂肪族羧酸形成。
无环脂肪族羧酸优选包含2至6个碳原子,最好是3至4个碳原子。
它们包括一元羧酸或二元羧酸。
一元羧酸可以被至少一个羟基基团取代。
优选的一元羧酸包括乙酸或L-乳酸(2(S)-羟基丙酸)。
二元羧酸也可以被至少一个羟基基团取代。
优选的二元羧酸包括酒石酸,L-苹果酸,琥珀酸,丙二酸,富马酸和戊二酸。
被至少一个羟基取代的一元或二元羧酸优选包括L-酒石酸,D-酒石酸,L-苹果酸,柠檬酸,或2(S)-羟基丙酸。
无环脂肪族羧酸也包括三元羧酸,如柠檬酸或含一个不饱和键的酸,如丙二酸。
Dendrogenin A与无环的脂肪族羧酸形成的酸加成盐可具有4至60毫克/毫升的在水中溶解度。
优选的无环脂肪族羧酸选自L-乳酸、丙二酸、L-苹果酸和酒石酸(D或L)。
Dendrogenin A与这样的酸形成的酸加成盐可具有35至65毫克/毫升的在水中溶解度。
本发明的Dendrogenin A的酸加成盐也可以由包含不超过8个碳原子例如甲磺酸酸的无环脂肪族磺酸形成。
本发明的Dendrogenin A的酸加成盐也可以由包含不超过4个芳基基团的芳族羧酸或磺酸形成。
包含不超过4个芳基基团的芳族羧酸或磺酸,优选含有不超过一个芳基基团,如苯磺酸,苯甲酸,或4-甲基苯磺酸。
Dendrogenin A与这样的酸所形成的酸加成盐可具有20至35毫克/毫升的在水中溶解度。
含有多达4个芳基基团的优选的芳族羧酸包括双羟萘酸(4,4’亚甲基双(3-羟基-2-萘甲酸))。
本发明还涉及一种药物组合物,其包含药学上可接受的载体和一种上述DendrogeninA的酸加成盐。
本发明还涉及一种上述Dendrogenin A的酸加成盐用于治疗神经退行性疾病、癌症或用于激活患者的免疫系统。
下列实施例举例说明根据本发明的Dendrogenin A酸加成盐的制备。
实施例1:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇盐酸盐:
将盐酸水溶液(0.9克,37%)加入到5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.14克,10毫摩尔)的乙醇溶液(10ml)中。在减压下将溶液蒸发至干,将所得残余物用甲醇重结晶。将产物滤出,并用乙醇重结晶,过滤,干燥后,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇盐酸盐,具有下列分析性质:分析结果:C,77.11;H,10.40;N,7.79;Cl,6.58%。H2O,1.75%。计算的C36H56C1N3O2-0.52H2O:C,77.09;H,10.37;N,7.78;Cl,6.57%。H2O,1.73%。
实施例2:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇L-酒石酸盐:
将5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.4克,10毫摩)加入到(2R,3R)2,3-二羟基丁二酸(L-(+)-酒石酸;Fluka公司;1.5克10毫摩尔)的乙醇(40毫升)溶液中。在减压下将溶液蒸发至干,将所得残余物用甲醇重结晶。将产物滤出,再结晶,过滤,干燥后,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇酒石酸盐,具有下列分析性质:分析结果:C,66.61;H,9.42;N,6.48%。H2O,2.23%。计算的C36H61N3O8-0.8H2O:C,66.60;H,9.46;N,6.48%。H2O,2.22%。
实施例3:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇L-苹果酸盐:
将5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.4克,10毫摩尔)加入到(2S)-(-)-羟基丁酸(1.34克10毫摩尔L-(-)-苹果酸;Fluka公司)的水/乙醇(1:1)(40毫升)溶液中。在减压下将溶液蒸发至干,将所得残余物从甲醇中重结晶。将产物滤出,再结晶,过滤,干燥后,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇苹果酸盐,具有下列分析性质:分析结果:C,67.22;H,9.53;N,6.51%。H2O,0.65%。计算的C36H61N3O7-0.23H2O:C,67.20;H,9.49;N,6.53%。H2O,0.64%。
实施例4:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇琥珀酸盐:
将5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.4克,10毫摩尔)加入到琥珀酸(琥珀酸;Fluka公司;1.18克10毫摩尔)的乙醇(40毫升)溶液中。将溶液加热至90℃,加水(18克)处理并过滤。冷却后,产物结晶,并过滤,干燥,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇琥珀酸盐,具有下列分析性质:分析结果:C,68.99;H,9.81;N,6.72%。H2O,0.78%。计算的C36H61N3O6-0.25H2O:C,68.95;H,9.74;N,6.70%。H2O,0.72%。
实施例5:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇苯甲酸盐:
将5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.4克,10毫摩尔)加入到苯甲酸(Flukα公司;1.22克10毫摩尔)的甲苯(40毫升)溶液中。该溶液被加热并过滤。冷却后,产物结晶,并过滤,干燥,得到浅棕色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇苯甲酸盐,具有以下分析性质:分析结果:C,73.73;H,9.66;N,6.63%。计算的C39H61N3O4:C,73.70;H,9.61;N,6.61%。
实施例6:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇苯磺酸盐:
将5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.4克,10毫摩尔)加入到苯磺酸(Fluka公司;1.61克10毫摩尔)的热甲苯(40毫升)的溶液中。在减压下将溶液蒸发至干,将所得残余物用乙醇-乙酸乙酯重结晶。将产物滤出并干燥,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇苯磺酸盐,具有以下分析性质:分析结果:C,72.80;H,9.89;N,5.77%。H2O,1.11%。计算的C38H61N3O5S-0.38H2O:C,72.78;H,9.85;N,5.75%。H2O,1.09%。
实施例7:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇双羟萘酸盐:
将5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.4克,10毫摩尔)和4,4’亚甲基双(3-羟基-2-萘甲酸)(Fluka公司;3.88克10毫摩尔)的混合物在乙醇(40m1)中加热。加入水(25毫升)。冷却后,产物结晶,并过滤,干燥,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇双羟萘酸盐,具有以下分析性质:分析结果:C,74.96;H,8.15;N,4.78%。H2O,2.37%。计算的C55H71N3O8-1.15H2O:C,74.93;H,8.08;N,4.77%。H2O,2.35%。
实施例8:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇戊二酸盐:
将1,5-戊二酸(戊二酸,Fluka公司,660毫克,5毫摩尔)的溶液加入到5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(2.57克,5毫摩尔)的热乙醇(100m1)溶液中。在减压下将溶液蒸发至干,将所得残余物用乙醇重结晶。将产物滤出并再结晶,过滤,干燥后,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇戊二酸盐,具有下列分析性质:分析结果:C,71.09;H,10.74;N,6.76%。H2O,3.38%。计算的C37H63N3O6-1.15H2O:C,71.07;H,10.68;N,6.72%H2O,3.31%。
实施例9:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇丙二酸盐:
将1,3-丙二酸(丙二酸,Fluka公司,520毫克,5毫摩尔)的溶液加入到5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(2.57克,5毫摩尔)的热乙醇(100ml)溶液中。在减压下将溶液蒸发至干,将所得残余物用乙醇重结晶。将产物滤出并再结晶,过滤,干燥后,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇丙二酸,具有以下的分析性质:分析结果:C,69.09;H,9.77;N,5.95%。H2O,1.53%。计算的C35H59N3O6-0.51H2O:C,69.05;H,9.70;N,5.92%。H2O,1.51%。
实施例10:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇富马酸盐:
将(反式)-丁烯二酸(富马酸,Fluka公司;1.16克,10毫摩尔)加入到5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.14克,10毫摩尔)的乙醇(20ml)溶液中。将溶液加热至90℃,加水(18克)处理并过滤。冷却后,产物结晶,并过滤干燥,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇富马酸盐,具有以下分析性质:分析结果:C,68.01;H,9.58;N,6.63%。H2O,1.05%。计算的C36H59N3O6-0.36H2O:C,67.98;H,6.58;N,6.61%。H2O,1.02%。
实施例11:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇硫酸盐:
将硫酸(Fluka公司,5ml,1M)的乙醇溶液加入到5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(2.57克,5毫摩尔)的热乙醇(100ml)溶液中。减压下将溶液蒸发至干,将所得残余物用乙醇重结晶。将产物滤出,并乙醇重结晶,过滤,干燥后,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇硫酸盐,具有下列分析性质:分析结果:C,62.84;H,9.39;N,6.94%。H2O,5.72%。计算的C32H57N3O6S-1.92H2O:C,62.81;H,9.32;N,6.87%。H2O,5.65%。
实施例12:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇甲苯磺酸盐:
将5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.4克,10毫摩尔)加入到4-甲基苯磺酸(甲苯磺酸,Fluka公司;克10毫摩尔)的热甲苯(40毫升)溶液中。在减压下将溶液蒸发至干,将所得残余物用乙醇-乙酸乙酯重结晶。将产物滤出并干燥,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇甲苯磺酸盐,具有以下分析性质:分析结果:C,69.52;H,9.39;N,6.28%。H2O,1.77%。计算的C39H63N3O5S-0.64H2O:C,69.49;H,9.35;N,6.24%。H2O,1.71%。
实施例13:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇甲磺酸盐:
将甲磺酸(甲磺酸,Fluka公司,5rnl,1M)的乙醇溶液加入到5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(2.57克,5毫摩尔)的热乙醇(100ml)溶液中。在减压下将溶液蒸发至干,将所得残余物用乙醇重结晶。将产物滤出,并乙醇重结晶,过滤,干燥后,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇甲磺酸盐,具有下列分析性质:分析结果:C,66.10;H,9.89;N,7.05%。H2O,1.63%。计算C34H59N3O5S-0.53H2O:C,66.06;H,9.84;N,7.01%。H2O,1.59%。
实施例14:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇乙酸盐:
将乙酸(西格玛,0.6克,10毫摩尔)加入到5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.14克,10毫摩尔)的乙醇(40ml)溶液中。在减压下将溶液蒸发至干,将所得残余物用甲醇重结晶。将产物滤出,并乙醇重结晶,过滤,干燥,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇乙酸盐,具有下列分析性质:分析结果:C,71.52;H,10.38;N,7.41%。H2O,0.44%。计算的C34H59N3O4-0.13H2O:C,71.50;H,10.34;N,7.36%。H2O,0.41%。
实施例15:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇柠檬酸盐:
将5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.4克,10毫摩尔)和2-羟基丙烷-1,2,3-三羧酸(Fluka公司;1.92克10毫摩尔)的混合物在乙醇(40ml)中加热。加入水(25毫升)。冷却后,产物结晶,并过滤,干燥,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇柠檬酸盐,具有以下分析性质:分析结果:C,66.06;H,9.19;N,6.12%。H2O,2.11%。计算的C38H63N3O9-0.78H2O:C,66.01;H,9.12;N,6.08%。H2O,2.03%。
实施例16:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇L-乳酸盐:
将5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.4克,10毫摩尔)和2(S)-羟基丙酸(L-乳酸,Fluka公司;3.88克10毫摩尔)的混合物在乙醇(40ml)中加热。在减压下将溶液蒸发至干,将所得残余物用丙酮-乙醇重结晶。将产物滤出并用乙酸乙酯重结晶,过滤,干燥后,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇乳酸盐,具有下列分析性质:分析结果:C,70.53;H,10.01;N,6.88%。H2O,0.43%。计算的C36H61N3O5-0.14H2O:C,70.50;H,9.96;N,6.85%。H2O,0.41%。
实施例17:5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(D)(-)酒石酸盐:
将5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇(5.4克,10毫摩尔)加入到(2S,3S)2,3-二羟基丁二酸(D-(-)-酒石酸;Fluka公司;1.5克10毫摩尔)的乙醇(40毫升)溶液中。在减压下将溶液蒸发至干,将所得残余物用乙醇重结晶。将产物滤出并再结晶,过滤,干燥,得到浅黄色结晶固体5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇-(D)-酒石酸盐,具有下列分析性质:分析结果:C,67.98;H,9.48;N,6.63%。H2O,4.29%。计算的C36H61N3O8-1.51H2O:C,67.94;H,9.59;N,6.61%。H2O,4.27%。
实施例18-水溶解度
实施例1-17的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐的在室温下的在水中溶解度是根据以下的方法测得:
取每个样品的足够量。将水(50%v/v)加入到每个样品中,并且将混合物于室温下振荡5小时。上清液通过过滤器过滤,并在必要时用水0.1%TFA/乙腈的混合溶液进行稀释得到样品溶液。样品溶液的浓度(mg/ml)的测定是通过使用校准曲线方法的高效液相色谱(HPLC),并把其作为室温下的在水中溶解度。
HPLC分析条件:
使用LC200系列PerkinElmer公司的装置和二极管阵列UV检测器、使用来自BischoffChromatography的Ultrasep C18RP100柱进行HPLC纯化和分析。
使用乙腈梯度(40%B8分钟,然后在20分钟内达到100%B;A为95:5水/乙腈,0.1%TFA;B为95:5乙腈/水0.1%TFA)进行HPLC分析,保留时间18.5分钟。流速为1毫升/分钟。
结果列于表1。作为比较,游离碱的溶解度为0.47毫克/毫升。
表1
实施例 | 室温下的在水中溶解度(mg/ml) |
1 | 23 |
2 | 42 |
3 | 46 |
4 | 28 |
5 | 31 |
6 | 31.5 |
7 | 1.4 |
8 | 11.2 |
9 | 55 |
10 | 16 |
11 | 18 |
12 | 24 |
13 | 11 |
14 | 4.5 |
15 | 7.9 |
16 | 65 |
17 | 37 |
Claims (14)
1.与选自下组的酸形成的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐:
-无机酸,
-包含不多于8个碳原子的无环脂肪族羧酸或磺酸,以及
-包含不超过4个芳基基团的芳族羧酸或磺酸。
2.根据权利要求1所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐,其中所述酸加成盐是与选自盐酸和硫酸的无机酸形成的。
3.根据权利要求1所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-33-醇的酸加成盐,其中所述酸加成盐是与包含2至6个碳原子、优选3至4个碳原子的无环脂肪族羧酸形成的。
4.根据权利要求3所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐,其中所述包含2至6个碳原子、优选3至4个碳原子的无环脂肪族羧酸是一元或二元羧酸。
5.根据权利要求3或4所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐,其中所述酸加成盐是与琥珀酸、戊二酸、丙二酸、富马酸或乙酸形成的。
6.根据权利要求3或4所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐,其中所述包含2至6个的碳原子、优选3至4个碳原子的无环脂肪族羧酸被至少一个-OH取代。
7.根据权利要求6所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐,其中所述的酸加成盐是与L-酒石酸、D-酒石酸、L-苹果酸、柠檬酸、或2(S)-羟基丙酸形成的。
8.根据权利要求1所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐,其中所述的酸加成盐是与选自甲磺酸的无环脂肪族磺酸形成的。
9.根据权利要求1所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-33-醇的酸加成盐,其中所述的酸加成盐是与包含不超过4个芳基基团的芳族羧酸形成的,其中至少一个所述芳基基团被至少一个-OH取代。
10.根据权利要求9所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐,其中所述的酸加成盐是与4,4’亚甲基双[3-羟基-2-萘甲酸形成的。
11.根据权利要求1所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐,其中所述的酸加成盐是与包含不超过3个芳基基团、优选不超过一个芳基基团的芳族羧酸或磺酸形成的。
12.根据权利要求11所述的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐,其中所述的酸加成盐是与苯磺酸、苯甲酸、或4-甲基苯磺酸形成的。
13.药物组合物,包含药学上可接受的载体和根据权利要求1-12任一项所述的酸加成盐。
14.用于治疗神经退行性疾病、癌症或用于激活患者免疫系统的根据权利要求1-12任一项所述的酸加成盐。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306346.5 | 2011-10-18 | ||
EP11306346 | 2011-10-18 | ||
PCT/EP2012/070588 WO2013057148A1 (en) | 2011-10-18 | 2012-10-17 | ACID ADDITION SALTS OF 5α-HYDROXY-6β-[2-(1H-IMIDAZOL-4-YL)ETHYLAMINO]CHOLESTAN-3β-OL |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103958541A true CN103958541A (zh) | 2014-07-30 |
Family
ID=47046604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280050955.7A Pending CN103958541A (zh) | 2011-10-18 | 2012-10-17 | 5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20140274984A1 (zh) |
EP (1) | EP2768841B1 (zh) |
JP (1) | JP2014530245A (zh) |
KR (1) | KR20140083014A (zh) |
CN (1) | CN103958541A (zh) |
AU (1) | AU2012324980B2 (zh) |
CA (1) | CA2852622A1 (zh) |
ES (1) | ES2650914T3 (zh) |
MX (1) | MX351610B (zh) |
RU (1) | RU2014119929A (zh) |
WO (1) | WO2013057148A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016532709A (ja) * | 2013-09-04 | 2016-10-20 | アフィシェム | 化学療法感受性又は化学療法抵抗性腫瘍の治療のためのデンドロゲニンa及び抗腫瘍薬 |
CA2939120A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
EP3515453A1 (en) * | 2016-09-22 | 2019-07-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
MX2022007164A (es) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Sales metálicas y usos de estas. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050222097A1 (en) * | 2002-04-19 | 2005-10-06 | Marc Poirot | Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity |
CN102344480A (zh) * | 2011-07-22 | 2012-02-08 | 中国人民解放军第三军医大学 | 树突化胺基甾醇一类物的合成方法 |
-
2012
- 2012-10-17 EP EP12775237.6A patent/EP2768841B1/en not_active Not-in-force
- 2012-10-17 CN CN201280050955.7A patent/CN103958541A/zh active Pending
- 2012-10-17 RU RU2014119929/04A patent/RU2014119929A/ru not_active Application Discontinuation
- 2012-10-17 AU AU2012324980A patent/AU2012324980B2/en not_active Ceased
- 2012-10-17 US US14/352,160 patent/US20140274984A1/en not_active Abandoned
- 2012-10-17 KR KR1020147012333A patent/KR20140083014A/ko not_active Application Discontinuation
- 2012-10-17 WO PCT/EP2012/070588 patent/WO2013057148A1/en active Application Filing
- 2012-10-17 JP JP2014536218A patent/JP2014530245A/ja active Pending
- 2012-10-17 ES ES12775237.6T patent/ES2650914T3/es active Active
- 2012-10-17 MX MX2014004744A patent/MX351610B/es active IP Right Grant
- 2012-10-17 CA CA2852622A patent/CA2852622A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050222097A1 (en) * | 2002-04-19 | 2005-10-06 | Marc Poirot | Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity |
CN102344480A (zh) * | 2011-07-22 | 2012-02-08 | 中国人民解放军第三军医大学 | 树突化胺基甾醇一类物的合成方法 |
Non-Patent Citations (3)
Title |
---|
JAMES SWARBRICK等: "《ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY》", 31 December 1996, article ""Salt Forms of Drugs and Adsorption"", pages: 453-499 * |
PHILIPPE DE MEDINA等: "Synthesis of New Alkylaminooxysterols with Potent Cell Differentiating Activities: Identification of Leads for the Treatment of Cancer and Neurodegenerative Diseases", 《J. MED. CHEM.》, vol. 52, no. 23, 22 September 2009 (2009-09-22), pages 7765 - 7777, XP009131948, DOI: doi:10.1021/jm901063e * |
SANDRINE SILVENTE-POIROT等: ""Dendrogenin A,a promising therapy for metastatic melanoma,involving the secretion of exosomes,enriched in HSP70 and tyrosinase,and immunogenic cell death"", 《PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH》, vol. 50, 30 April 2009 (2009-04-30), pages 1130, XP009131953 * |
Also Published As
Publication number | Publication date |
---|---|
RU2014119929A (ru) | 2015-11-27 |
AU2012324980A1 (en) | 2014-05-01 |
MX2014004744A (es) | 2015-05-15 |
ES2650914T3 (es) | 2018-01-23 |
AU2012324980B2 (en) | 2017-09-21 |
EP2768841B1 (en) | 2017-09-27 |
CA2852622A1 (en) | 2013-04-25 |
WO2013057148A1 (en) | 2013-04-25 |
US20140274984A1 (en) | 2014-09-18 |
MX351610B (es) | 2017-10-20 |
JP2014530245A (ja) | 2014-11-17 |
EP2768841A1 (en) | 2014-08-27 |
KR20140083014A (ko) | 2014-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103958541A (zh) | 5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐 | |
CN105853356B (zh) | Jak抑制剂的局部用制剂 | |
CN100558723C (zh) | 4-[(4-甲基-1-哌嗪基)甲基]-n-[4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]苯基]-苯甲酰胺的盐形式 | |
WO2007009799A1 (de) | Aminosäuresalze von rosiglitazon | |
EP1613571B1 (de) | Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel | |
RU2013103768A (ru) | Новая полиморфная форма кальциметического соединения | |
EP1140197B1 (en) | Soluble compositions of toremifene | |
WO2009152712A1 (zh) | 长春氟宁盐、其制备方法及其药物组合物 | |
DK2946781T3 (en) | CRYSTALLINIC LEVOFOLIC ACID AND PROCEDURE FOR ITS PREPARATION | |
CN106905408B (zh) | 1-羰基丹参酮iia衍生物及其制备 | |
AU2012313987B2 (en) | Pure S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,-5H-benzo(i,j)quinolizine-2- carboxylic acid L-arginine salt tetrahydrate and a process for its preparation | |
CN113980020B (zh) | 一种酒石酸伐尼克兰晶型的制备方法 | |
RU2536425C2 (ru) | Фармацевтическая композиция, содержащая силденафил цитрат, и способ ее приготовления | |
CN102633660A (zh) | 一种琥珀酸美托洛尔的新晶型 | |
CN101659629A (zh) | 鱼腥草素类高水溶性、稳定性前体药物及其制备方法与运用 | |
CN108558676B (zh) | 一种n,n-二苄基乙二胺二乙酸盐的制备方法 | |
US20080287447A1 (en) | Methods for preparing eszopiclone | |
AU2014289182A1 (en) | Nalmefene salts as medicaments for reducing alcohol consumption or for preventing excessive alcohol consumption | |
CN111718324A (zh) | 基于苯丙咪唑羧酸化合物的组合物及其应用 | |
CN104224794B (zh) | 一种托伐普坦组合物及其制备方法 | |
CN117942338A (zh) | 同位素富集的化合物在pros上的药物应用 | |
CN103833747A (zh) | 黄连碱衍生物的盐 | |
CN103570715A (zh) | 钩藤生物碱衍生物的盐 | |
CN103864806A (zh) | 克班宁衍生物的盐 | |
CN103910724A (zh) | 苦木生物碱衍生物的盐 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140730 |